celecoxib has been researched along with Head and Neck Neoplasms in 32 studies
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-dependent cardiac toxicity limits long-term use of celecoxib." | 5.42 | The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. ( Chen, Z; Hu, R; Huang, Y; Jiang, H; Jiang, J; Xu, H; Yan, J; Yang, Y; Zhang, Y, 2015) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 5.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "Eligible patients had head and neck cancers requiring palliative chemotherapy with ECOG PS 0-2 and adequate organ functions who could not afford cetuximab." | 2.80 | A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. ( Arya, S; Banavali, S; Bhattacharjee, A; Bhosale, B; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Muddu, VK; Noronha, V; Patil, VM; Prabhash, K, 2015) |
| " We conducted a phase I and pharmacokinetic study with the erlotinib and celecoxib combination in patients with advanced premalignant lesions." | 2.79 | Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ( Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y, 2014) |
| "The combined treatment inhibited head and neck cancer cell growth significantly more potently than either single agent alone in cell line and xenograft models, and resulted in greater inhibition of cell-cycle progression at G1 phase than either single drug." | 2.78 | Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. ( Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H, 2013) |
| "Celecoxib was administered throughout the radiotherapy course." | 2.76 | Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. ( Cvek, J; Dusek, L; Feltl, D; Halamka, M; Horacek, J; Kominek, P; Kubes, J; Zavadova, E, 2011) |
| "Treatment with celecoxib in the postoperative setting was associated with decreased mean use of opioids in oral (mean difference, 9." | 1.48 | Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction. ( Buchmann, LO; Cannon, RB; Carpenter, PS; Hunt, JP; Kull, A; McCrary, H; Monroe, MM; Shepherd, HM; Torrecillas, V, 2018) |
| " Dose-dependent cardiac toxicity limits long-term use of celecoxib." | 1.42 | The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. ( Chen, Z; Hu, R; Huang, Y; Jiang, H; Jiang, J; Xu, H; Yan, J; Yang, Y; Zhang, Y, 2015) |
| " Dose-dependent cardiac toxicity limits long-term use of celecoxib, but it seems likely that this may be diminished by lowering its dose." | 1.36 | Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. ( Califano, JA; Fang, Y; Gu, X; Guo, Y; Hao, Y; Ji, H; Pang, X; Sha, W; Southerland, WM; Zhao, Y; Zhou, Y, 2010) |
| "Skin cancer is the most common cancer, and often occurs in the head and neck region." | 1.35 | Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 1.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "We used pairs of head and neck squamous cell carcinoma (HNSCC) cell lines derived from primary and metastatic tumors of the same patient to analyze eicosanoid metabolites by ESI-LC/MS/MS and COX/LOX expression by western immunoblotting." | 1.32 | Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. ( Lotan, R; Newman, RA; Schroeder, CP; Yang, P, 2004) |
| "Celecoxib-treated tumors showed reduced proliferation and increased apoptosis of both tumor and stromal cells compared with vehicle controls." | 1.31 | Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. ( Davis, TW; Masferrer, JL; Ornberg, RL; Zweifel, BS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 17 (53.13) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Kamal, MV | 1 |
| Rao, M | 1 |
| Damerla, RR | 1 |
| Pai, A | 1 |
| Sharan, K | 1 |
| Palod, A | 1 |
| Shetty, PS | 1 |
| Usman, N | 1 |
| Kumar, NAN | 1 |
| Gehrke, T | 1 |
| Scherzad, A | 1 |
| Hackenberg, S | 1 |
| Ickrath, P | 1 |
| Schendzielorz, P | 1 |
| Hagen, R | 1 |
| Kleinsasser, N | 1 |
| Carpenter, PS | 1 |
| Shepherd, HM | 1 |
| McCrary, H | 1 |
| Torrecillas, V | 1 |
| Kull, A | 1 |
| Hunt, JP | 1 |
| Monroe, MM | 1 |
| Buchmann, LO | 1 |
| Cannon, RB | 1 |
| Shin, DM | 5 |
| Zhang, H | 1 |
| Saba, NF | 2 |
| Chen, AY | 2 |
| Nannapaneni, S | 2 |
| Amin, AR | 1 |
| Müller, S | 2 |
| Lewis, M | 2 |
| Sica, G | 2 |
| Kono, S | 1 |
| Brandes, JC | 1 |
| Grist, WJ | 1 |
| Moreno-Williams, R | 2 |
| Beitler, JJ | 2 |
| Thomas, SM | 1 |
| Chen, Z | 5 |
| Shin, HJ | 3 |
| Grandis, JR | 3 |
| Khuri, FR | 3 |
| Chen, ZG | 3 |
| Patil, V | 1 |
| Noronha, V | 2 |
| Krishna, V | 1 |
| Joshi, A | 2 |
| Prabhash, K | 2 |
| Abrahão, AC | 1 |
| Giudice, FS | 1 |
| Sperandio, FF | 1 |
| Pinto Junior, Ddos S | 1 |
| Hurwitz, SJ | 1 |
| Kono, SA | 1 |
| Yang, CS | 1 |
| Zhao, Y | 2 |
| Grist, W | 1 |
| Moore, CE | 1 |
| Owonikoko, TK | 1 |
| Ramalingam, S | 1 |
| Wirth, LJ | 2 |
| Lalla, RV | 1 |
| Choquette, LE | 1 |
| Curley, KF | 1 |
| Dowsett, RJ | 1 |
| Feinn, RS | 1 |
| Hegde, UP | 1 |
| Pilbeam, CC | 1 |
| Salner, AL | 1 |
| Sonis, ST | 1 |
| Peterson, DE | 1 |
| Qian, M | 1 |
| Qian, D | 1 |
| Jing, H | 1 |
| Li, Y | 1 |
| Ma, C | 1 |
| Zhou, Y | 2 |
| Patil, VM | 1 |
| Muddu, VK | 1 |
| Dhumal, S | 1 |
| Bhosale, B | 1 |
| Arya, S | 1 |
| Juvekar, S | 1 |
| Banavali, S | 1 |
| D'Cruz, A | 1 |
| Bhattacharjee, A | 1 |
| Yang, Y | 1 |
| Yan, J | 1 |
| Huang, Y | 1 |
| Xu, H | 1 |
| Zhang, Y | 1 |
| Hu, R | 1 |
| Jiang, J | 1 |
| Jiang, H | 1 |
| Fegn, L | 1 |
| Wang, Z | 2 |
| Kim, YY | 1 |
| Lee, EJ | 1 |
| Kim, YK | 1 |
| Kim, SM | 1 |
| Park, JY | 1 |
| Myoung, H | 1 |
| Kim, MJ | 1 |
| Hao, Y | 1 |
| Ji, H | 1 |
| Fang, Y | 1 |
| Guo, Y | 1 |
| Sha, W | 1 |
| Pang, X | 1 |
| Southerland, WM | 1 |
| Califano, JA | 1 |
| Gu, X | 1 |
| Park, SW | 1 |
| Kim, HS | 1 |
| Hah, JW | 1 |
| Jeong, WJ | 1 |
| Kim, KH | 1 |
| Sung, MW | 1 |
| Kao, J | 1 |
| Genden, EM | 1 |
| Chen, CT | 1 |
| Rivera, M | 1 |
| Tong, CC | 1 |
| Misiukiewicz, K | 1 |
| Gupta, V | 1 |
| Gurudutt, V | 1 |
| Teng, M | 1 |
| Packer, SH | 1 |
| Halamka, M | 1 |
| Cvek, J | 1 |
| Kubes, J | 1 |
| Zavadova, E | 1 |
| Kominek, P | 1 |
| Horacek, J | 1 |
| Dusek, L | 1 |
| Feltl, D | 1 |
| Lubet, RA | 1 |
| Clapper, ML | 1 |
| McCormick, DL | 1 |
| Pereira, MA | 1 |
| Chang, WC | 1 |
| Steele, VE | 1 |
| Fischer, SM | 1 |
| Juliana, MM | 1 |
| Grubbs, CJ | 1 |
| Zweifel, BS | 1 |
| Davis, TW | 1 |
| Ornberg, RL | 1 |
| Masferrer, JL | 1 |
| Mohan, S | 1 |
| Epstein, JB | 1 |
| Hashitani, S | 1 |
| Urade, M | 1 |
| Nishimura, N | 1 |
| Maeda, T | 1 |
| Takaoka, K | 1 |
| Noguchi, K | 1 |
| Sakurai, K | 1 |
| Schroeder, CP | 1 |
| Yang, P | 1 |
| Newman, RA | 1 |
| Lotan, R | 1 |
| Zhang, X | 3 |
| Li, M | 1 |
| Wieand, HS | 2 |
| Lippman, SM | 1 |
| Gibson, N | 1 |
| Subbaramaiah, K | 1 |
| Dannenberg, AJ | 1 |
| Choe, MS | 2 |
| Lin, Y | 1 |
| Sun, SY | 1 |
| Chen, A | 1 |
| Raju, U | 1 |
| Ariga, H | 1 |
| Dittmann, K | 1 |
| Nakata, E | 1 |
| Ang, KK | 1 |
| Milas, L | 1 |
| Haddad, RI | 1 |
| Lindeman, NI | 1 |
| Zhao, X | 1 |
| Lee, JC | 1 |
| Joshi, VA | 1 |
| Norris, CM | 1 |
| Posner, MR | 1 |
| Bock, JM | 1 |
| Menon, SG | 1 |
| Sinclair, LL | 1 |
| Bedford, NS | 1 |
| Goswami, PC | 1 |
| Domann, FE | 1 |
| Trask, DK | 1 |
| Klass, CM | 1 |
| Lai, V | 1 |
| George, J | 1 |
| Richey, L | 1 |
| Kim, HJ | 1 |
| Cannon, T | 1 |
| Shores, C | 1 |
| Couch, M | 1 |
| Fong, LY | 1 |
| Jiang, Y | 1 |
| Riley, M | 1 |
| Liu, X | 1 |
| Smalley, KJ | 1 |
| Guttridge, DC | 1 |
| Farber, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers[NCT00314262] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Cyclooxygenase-2 Inhibition in Radiation-Induced Oral Mucositis[NCT00698204] | Phase 2 | 43 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278] | 60 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response evaluation was based on pathologic examination of the degree of dysplasia observed and recorded by an expert head and neck pathologist. Pathologic complete response was defined as complete disappearance of dysplasia from the epithelium. Pathologic partial response was defined as improvement of dysplasia by at least one degree (i.e., severe dysplasia becomes moderate dysplasia). Pathologic minor response or stable disease was defined as minor focal improvement without change of degree of dysplasia (i.e., focal improvement from moderate to mild dysplasia with still moderate dysplasia overall) or no pathologic changes after treatment. Pathologic progressive disease was defined as worsening by at least one degree of dysplasia (i.e., mild to moderate dysplasia) or development of invasive cancer on or following treatment. (NCT00314262)
Timeframe: 12 months from time of enrollment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete remission (CR) | Partial remission (PR) | Progressive disease (PD) | Stable disease (SDi) | |
| Erlotinib & Celecoxib | 3 | 1 | 1 | 2 |
Response evaluation was based on pathologic examination of the degree of dysplasia observed and recorded by an expert head and neck pathologist. Pathologic complete response was defined as complete disappearance of dysplasia from the epithelium. Pathologic partial response was defined as improvement of dysplasia by at least one degree (i.e., severe dysplasia becomes moderate dysplasia). Pathologic minor response or stable disease was defined as minor focal improvement without change of degree of dysplasia (i.e., focal improvement from moderate to mild dysplasia with still moderate dysplasia overall) or no pathologic changes after treatment. Pathologic progressive disease was defined as worsening by at least one degree of dysplasia (i.e., mild to moderate dysplasia) or development of invasive cancer on or following treatment. (NCT00314262)
Timeframe: Up to 55 months from initiation of therapy. Median duration of follow-up was 36 months.
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Stage I invasive carcinoma | Stage II oral cavity carcinoma | Invasive squamous cell carcinoma | Recurrent moderate dysplasia | Recurrent severe dysplasia | Recurrent high-grade dysplasia | Complete remission | |
| Erlotinib & Celecoxib | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Participants received a fixed dose of celecoxib 400 mg orally BID continuously for 6 months. Erlotinib was dose escalated at 3 dose levels of 50, 75, and 100 mg orally every day for 6 months. Dose escalation followed a standard 3+3 escalation design. (NCT00314262)
Timeframe: 12 months from time of enrollment
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal cramping, Grade 1 | Alopecia, Grade 1 | Anemia, Grade 1 | Anemia, Grade 2 | Anxiety, Grade 1 | Decreased protein, Grade 1 | Leukopenia, Grade 1 | Leukopenia, Grade 2 | Depression, Grade 1 | Diarrhea, Grade 1 | Dry eyes, Grade 1 | Dry skin, Grade 1 | Elevated LDH, Grade 1 | Elevated serum creatinine, Grade 1 | Elevated serum creatinine, Grade 2 | Elevated alkaline phosphatase, Grade 1 | Elevated ALT, Grade 1 | Elevated AST, Grade 4 | Fatigue, Grade 1 | Hyperbilirubinemia, Grade 1 | Hypercholesterolemia, Grade 1 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hypoalbuminemia, Grade 1 | Hypoalbuminemia, Grade 2 | Hypocalcemia, Grade 1 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypokalemia, Grade 1 | Hyponatremia, Grade 1 | Mouth sores, Grade 1 | Mouth sores, Grade 2 | Mucositis, Grade 1 | Mucositis, Grade 3 | Nausea, Grade 1 | Neuropathy, Grade 1 | Pruritis, Grade 1 | Rash, Grade 1 | Rash, Grade 3 | Shortness of breath, Grade 1 | Strep throat, Grade 2 | Urosepsis, Grade 3 | Vomiting, Grade 1 | |
| Erlotinib & Celecoxib | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 3 | 5 | 4 | 6 | 3 | 4 | 1 | 3 | 5 | 4 | 6 | 2 | 2 | 7 | 2 | 3 | 1 | 4 | 1 | 1 | 2 | 3 | 9 | 3 | 3 | 1 | 4 | 3 | 2 | 8 | 2 | 3 | 1 | 1 | 2 |
"Oral Mucositis Assessment Scale (OMAS) was used to assess oral mucosal injury during the period of radiation therapy. This validated scale scores ulceration and erythema independently at nine specified sites in the oral cavity. Ulceration is scored from 0-3 based on size of lesion and erythema is scored from 0-2 based on severity of erythema. The sum of scores is then divided by 9.~The mean OMAS score at a cumulative radiation dose of 5000 cGy (approximately 5 weeks of treatment) was compared between groups." (NCT00698204)
Timeframe: 5 weeks from start of radiation therapy (5000 cGy)
| Intervention | units on a scale (Mean) |
|---|---|
| I- Celecoxib | 1.42 |
| II- Placebo | 1.36 |
Mean worst pain at 5000 cGy on 0-10 scale, 0 = no pain, 10 = worst pain imaginable (NCT00698204)
Timeframe: 5 weeks from start of radiation therapy (cumulative dose of 5000 cGy)
| Intervention | units on a scale (Mean) |
|---|---|
| I- Celecoxib | 4.47 |
| II- Placebo | 3.70 |
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
| Intervention | participants (Number) |
|---|---|
| Celecoxib 200mg | 0 |
| Celecoxib 400mg | 1 |
| Celecoxib 600mg | 2 |
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
| Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| locoregional control | progress-free survival | overall survival rates | long term toxicity | |
| Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
| Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
2 reviews available for celecoxib and Head and Neck Neoplasms
| Article | Year |
|---|---|
A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Head and Neck N | 2023 |
Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous | 2003 |
8 trials available for celecoxib and Head and Neck Neoplasms
| Article | Year |
|---|---|
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Sq | 2013 |
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer.
Topics: Adult; Aged; Celecoxib; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle A | 2014 |
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Ant | 2015 |
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB | 2011 |
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB | 2011 |
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB | 2011 |
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB | 2011 |
Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Clinical Trials, Phase II as Topic; Combined Modal | 2011 |
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2005 |
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
Topics: Body Mass Index; Body Weight; C-Reactive Protein; Cachexia; Celecoxib; Cyclooxygenase Inhibitors; Cy | 2008 |
22 other studies available for celecoxib and Head and Neck Neoplasms
| Article | Year |
|---|---|
Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell | 2017 |
Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction.
Topics: Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Free Tissue Fl | 2018 |
Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2013 |
Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cultu | 2013 |
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention | 2014 |
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Ce | 2014 |
The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Survival; Cetuxim | 2015 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy | 2009 |
Anti-cancer effects of celecoxib in head and neck carcinoma.
Topics: Animals; Celecoxib; Cell Death; Cell Line, Tumor; Chemoprevention; Cricetinae; Cyclooxygenase 2; Cyc | 2010 |
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2010 |
Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cy | 2010 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Co | 2012 |
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Ce | 2002 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Dose-Response Re | 2004 |
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase | 2004 |
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenas | 2005 |
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenas | 2005 |
Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib.
Topics: Blotting, Western; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; DNA; DNA Repair; DNA-Acti | 2005 |
Celecoxib toxicity is cell cycle phase specific.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Growth Processes; Cyclin-Dependent Kin | 2007 |
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumo | 2007 |
Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2008 |